101 related articles for article (PubMed ID: 10847827)
1. N-acetylcysteine for chronic obstructive pulmonary disease?
Lavietes MH
Respiration; 1999; 66(6):491-2. PubMed ID: 10847827
[No Abstract] [Full Text] [Related]
2. N-acetylcysteine reduces the exacerbation rate in patients with moderate to severe COPD.
Pela R; Calcagni AM; Subiaco S; Isidori P; Tubaldi A; Sanguinetti CM
Respiration; 1999; 66(6):495-500. PubMed ID: 10575333
[TBL] [Abstract][Full Text] [Related]
3. IV versus oral N-acetylcysteine.
Gupta AK; Su MK; Greller HA; Lee DC; Chan GM
Ann Emerg Med; 2009 Dec; 54(6):857-8; author reply 858-9. PubMed ID: 19942075
[No Abstract] [Full Text] [Related]
4. Regarding "comparison of the 20-hour intravenous and 72-hour oral acetylcysteine protocols for the treatment of acute acetaminophen poisoning" by Yarema et al.
Hernandez SH; Ghaffari G; Connors NJ; Howland MA; Hoffman RS
Ann Emerg Med; 2009 Dec; 54(6):856-7. PubMed ID: 19942074
[No Abstract] [Full Text] [Related]
5. N-acetylcysteine in COPD may be beneficial, but for whom?
Cazzola M; Matera MG
Lancet Respir Med; 2014 Mar; 2(3):166-7. PubMed ID: 24621673
[No Abstract] [Full Text] [Related]
6. Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial.
Zheng JP; Wen FQ; Bai CX; Wan HY; Kang J; Chen P; Yao WZ; Ma LJ; Li X; Raiteri L; Sardina M; Gao Y; Wang BS; Zhong NS;
Lancet Respir Med; 2014 Mar; 2(3):187-94. PubMed ID: 24621680
[TBL] [Abstract][Full Text] [Related]
7. N-acetylcysteine for COPD: the evidence remains inconclusive.
Turner RD; Bothamley GH
Lancet Respir Med; 2014 Apr; 2(4):e3. PubMed ID: 24717631
[No Abstract] [Full Text] [Related]
8. N-acetylcysteine for COPD: the evidence remains inconclusive--authors' reply.
Zheng JP; Zhong NS
Lancet Respir Med; 2014 Apr; 2(4):e3-4. PubMed ID: 24717632
[No Abstract] [Full Text] [Related]
9. [N-Acetylcysteine: low and high doses in the treatment of chronic obstructive lung diseases in Chernobyl accident liquidators].
Chikina SIu; Iagmurov BKh; Kopylev ID; Soodaeva SK; Chuchalin AG
Ter Arkh; 2002; 74(3):62-5. PubMed ID: 11980127
[TBL] [Abstract][Full Text] [Related]
10. Oral N-acetylcysteine: how does it act?
Richardson P
Eur J Respir Dis; 1987 Feb; 70(2):71-2. PubMed ID: 3817073
[No Abstract] [Full Text] [Related]
11. Is the oral acetylcysteine protocol the best treatment for late-presenting acetaminophen poisoning?
Bond GR
Ann Emerg Med; 2009 Oct; 54(4):615-7. PubMed ID: 19695740
[No Abstract] [Full Text] [Related]
12. Skin rash after oral N-acetylcysteine for kidney protection.
Jabr FI
Int J Dermatol; 2014 Mar; 53(3):e189-90. PubMed ID: 23621680
[No Abstract] [Full Text] [Related]
13. N-Acetylcysteine versus fenoldopam mesylate to prevent contrast agent-associated nephrotoxicity.
Briguori C; Colombo A; Airoldi F; Violante A; Castelli A; Balestrieri P; Paolo Elia P; Golia B; Lepore S; Riviezzo G; Scarpato P; Librera M; Focaccio A; Ricciardelli B
J Am Coll Cardiol; 2004 Aug; 44(4):762-5. PubMed ID: 15312855
[TBL] [Abstract][Full Text] [Related]
14. Genetics affect IPF treatment response to N-acetylcysteine.
Lozano-Wilhelmi M
Lancet Respir Med; 2015 Oct; 3(10):752. PubMed ID: 26388174
[No Abstract] [Full Text] [Related]
15. [Antioxidative and clinical effects of high-dose N-acetylcysteine in fibrosing alveolitis. Adjunctive therapy to maintenance immunosuppression].
Entzian P
Pneumologie; 1998 Jul; 52(7):396-7. PubMed ID: 9738391
[No Abstract] [Full Text] [Related]
16. Intravenous acetylcysteine for the treatment of acetaminophen overdose.
Klein-Schwartz W; Doyon S
Expert Opin Pharmacother; 2011 Jan; 12(1):119-30. PubMed ID: 21126198
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the 20-hour intravenous and 72-hour oral acetylcysteine protocols for the treatment of acute acetaminophen poisoning.
Yarema MC; Johnson DW; Berlin RJ; Sivilotti ML; Nettel-Aguirre A; Brant RF; Spyker DA; Bailey B; Chalut D; Lee JS; Plint AC; Purssell RA; Rutledge T; Seviour CA; Stiell IG; Thompson M; Tyberg J; Dart RC; Rumack BH
Ann Emerg Med; 2009 Oct; 54(4):606-14. PubMed ID: 19556028
[TBL] [Abstract][Full Text] [Related]
18. Long-term administration of N-acetylcysteine decreases hydrogen peroxide exhalation in subjects with chronic obstructive pulmonary disease.
Kasielski M; Nowak D
Respir Med; 2001 Jun; 95(6):448-56. PubMed ID: 11421501
[TBL] [Abstract][Full Text] [Related]
19. N-acetyl cysteine in liver resection.
Mohamed ZU; Krishnakumar L; Sudhindran S
J Surg Oncol; 2016 Nov; 114(6):773. PubMed ID: 27652587
[No Abstract] [Full Text] [Related]
20. [Acetylcysteine (Fluimucil) in the treatment of COPD of the horse].
Breuer D; Becker M
Tierarztl Prax; 1983; 11(2):209-12. PubMed ID: 6868068
[No Abstract] [Full Text] [Related]
[Next] [New Search]
